Clearside Biomedical, Inc. (CLSD)

US — Healthcare Sector
Peers: PNT  ORIC  LYRA  INBX  EPIX  SNSE  NXTC  NUVB  GRPH  MACK  GRCL  THRX  GLUE  DSGN  ERAS  EYEN  DRTS  OCUL  TNYA  INZY  GBIO  KRON  CCCC  EWTX 

Automate Your Wheel Strategy on CLSD

With Tiblio's Option Bot, you can configure your own wheel strategy including CLSD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CLSD
  • Rev/Share 0.0186
  • Book/Share -0.5968
  • PB -1.2734
  • Debt/Equity -0.0135
  • CurrentRatio 3.1852
  • ROIC -1.7622

 

  • MktCap 59058460.0
  • FreeCF/Share -0.3068
  • PFCF -2.5028
  • PE -1.8974
  • Debt/Assets 0.0315
  • DivYield 0
  • ROE 0.8336

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation CLSD Chardan Capital Markets -- Buy -- $6 Aug. 21, 2024

News

Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
CLSD
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
CLSD
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m.

Read More
image for news Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
CLSD
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral

Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases

Read More
image for news Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
CLSD
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter.

Read More
image for news Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
CLSD
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative

Clearside Biomedical (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
CLSD
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025, at 1:00 p.m. ET.

Read More
image for news Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

About Clearside Biomedical, Inc. (CLSD)

  • IPO Date 2016-06-02
  • Website https://www.clearsidebio.com
  • Industry Biotechnology
  • CEO Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
  • Employees 32

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.